Nov 8 (Reuters) - Adalta Ltd (1AD) :
- Commercialisation agreement with crossbeta biosciences
- Will receive royalties on future revenues from commercialization of aßo-specific shark antibodies as novel therapeutics or diagnostic agents
- Under terms of agreement, crossbeta has been granted an exclusive license to three beta-amyloid oligomer (aßo)-specific shark antibodies
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.001(25.0%) |
Mkt cap ! $2.782M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $190 | 75.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 6258466 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 15952546 | 18 |
View Market Depth
| Last trade - 15.12pm 31/07/2025 (20 minute delay) ? |
| 1AD (ASX) Chart |